Drug Trial Radar · NCT06049030
A Study of HS-10516 in Patients With Advanced Clear Cell Renal Cell Carcinoma
Last checked: Nov 19, 2026Latest source record: Sep 26, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
190
Planned (sponsor's estimate)
Start
Sep 25, 2023
Primary completion
Sep 25, 2024
Study completion Sep 25, 2025
Sponsor
- Lead sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 21, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of the Phase Ia portion is to identify the maximum tolerated dose or maximum acceptable dose MTD/MAD of HS-10516. The phase Ib portion will evaluate the preliminary efficacy of HS-10516 in ccRCC.
Conditions
- Renal Cell Carcinoma
Interventions
HS-10516Drug
Oral HIF-2α inhibitor
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase Ia: MTD/MAD of HS-10516Time frame: Approximately 2 months
- Phase Ib: Objective Response Rate (ORR) by Independent Review Committee (IRC)Time frame: Approximately 1 year
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.